Antimicrobial Peptide Tyrothricin Shows Activity Against Toxoplasma Parasite | Research

The takeaway

The antimicrobial peptide mixture tyrothricin demonstrated in vitro activity against Toxoplasma gondii tachyzoites, identifying potential molecular targets in the parasite.

In vitro parasite killing
Tyrothricin inhibits Toxoplasma gondii growth with identified molecular targets

What the researchers found

Tyrothricin inhibited T. gondii tachyzoite proliferation in vitro, with proteomics identifying potential molecular targets in the parasite.

Why it matters

Toxoplasmosis treatment options are limited and often toxic. Antimicrobial peptides could offer new therapeutic approaches for this common parasitic infection.

How the study worked

In vitro study combining proliferation inhibition assays, electron microscopy, host cell and embryo toxicity testing, and differential affinity chromatography with mass spectrometry.

What this study cannot tell us

In vitro study only — no in vivo animal infection model; tyrothricin is typically used topically, and systemic use may face toxicity challenges.

How to read the evidence

In vitro laboratory study — proof of concept for antiparasitic activity, far from clinical application.

When this study was published

Published 2026 in Biomedicines.

The bigger picture

Repurposing antimicrobial peptides for parasitic infections could expand the therapeutic arsenal against drug-resistant and poorly treated parasitic diseases.

Questions still open

Can tyrothricin components be modified for systemic anti-parasitic use?
Do the identified molecular targets offer opportunities for targeted drug design?

Common questions

What is Toxoplasma gondii?

It's a parasite that infects roughly a third of the world's population, usually from undercooked meat or cat feces. Most people show no symptoms, but it can be dangerous for pregnant women and immunocompromised individuals.

Could antimicrobial peptides replace antibiotics for parasites?

Potentially — peptides like tyrothricin show activity against parasites in lab tests, but significant development is needed before they could be used as clinical treatments.

Read the original research

Potential Molecular Targets of the Broad-Range Antimicrobial Peptide Tyrothricin in the Apicomplexan Parasite Toxoplasma gondii.

Biomedicines, 14(1)

View on PubMed ↗Publisher’s paper ↗

Citation

Amdouni, Yosra; Boubaker, Ghalia; Müller, Joachim; Sousa, Maria Cristina Ferreira de; Hänggeli, Kai Pascal Alexander; Uldry, Anne-Christine; Braga-Lagache, Sophie; Heller, Manfred; Hemphill, Andrew. (2026). Potential Molecular Targets of the Broad-Range Antimicrobial Peptide Tyrothricin in the Apicomplexan Parasite Toxoplasma gondii.. Biomedicines, 14(1). https://doi.org/10.3390/biomedicines14010172